ICU MedicalICUI
Recorded

ICU Medical 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration43 minParticipants10

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon, everyone, and welcome to today's ICU Medical Inc. third quarter 2026 earnings conference call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. To ask a question at that time, please press star one. Also, please note that today's event is being recorded. I'd now like to turn the conference over to Deirdre Thomson, ICR Senior Vice President.

Deirdre ThomsonSVP of Investor Relations

Please go ahead. Thank you for joining us to discuss ICU Medical's financial results for the third quarter of 2026.

Deirdre ThomsonSVP of Investor Relations

On the call today representing ICU Medical is Vivek Jain, Chief Executive Officer and Chairman, and Brian Bonnell, Chief Financial Officer. We wanted to let everyone know that we have a presentation accompanying today's prepared remarks. To view the presentation, please go to our investor page and click on Events Calendar, and it will be under third quarter 2026 events. Before we start our prepared remarks, we want to touch upon any forward-looking statements made during the call, including beliefs and expectations about the company's future results. Please be aware they are based on the best available information to management and assumptions that are reasonable. Such statements are not intended to be a representation of future results and are subject to risk and uncertainties. Future results may differ materially from management's current expectations.

Deirdre ThomsonSVP of Investor Relations

We refer all of you to the company's SEC filings for more detailed information on the risk and uncertainties that have a direct bearing on operating results and financial position. Please note that during today's call, we will also discuss non-GAAP financial measures, including results on an adjusted basis. We believe these financial measures can facilitate a more complete analysis and greater transparency into ICU Medical's ongoing results of operations, particularly when comparing underlying results from period to period. We've also included a reconciliation of these non-GAAP measures in today's release and provide as much detail as possible on any addendums that are added back. With that, it is my pleasure to turn the call over to Vivek.

Vivek JainCEO and Chairman

Thanks, Deirdre, and good afternoon, everyone. I'll walk through our Q3 revenue and earnings performance and provide some color on the businesses, and then turn it over to Brian, who will recap the full Q3 results. After that, I'll come back with a few updates on product development initiatives and some comments on our performance against our near and midterm financial goals and our latest capital allocation strategy. Revenue for Q3 was $556 million for total company growth of 5% on an organic basis, or 4% reported, as the reported results are no longer impacted by the mid-2025 creation of the Otsuka ICU Medical joint venture and the resulting deconsolidation of IV Solutions from our income statement. Adjusted gross margins were strong at just over 42%. Adjusted EBITDA improved to $114 million, and adjusted EPS was $2.44.

Vivek JainCEO and Chairman

Organic free cash flow was again healthy, and when combined with tariff refunds, which are excluded from our P&L commentary today, we were able to repay approximately $80 million of debt in the quarter and will finish 2026 slightly below two times net leverage. The broader demand and utilization environment in Q3 continued to be stable, with volume in line with our guidance assumptions for the year. The capital environment is status quo, and it does appear investments that customers need to get done do get done. The only change in currency since the last call is the strengthening dollar against the euro. During Q3, we did move forward consolidating the legacy Smiths physical distribution and logistics into a common network. We did have some operational bumps, which were more impactful in the international markets.

Vivek JainCEO and Chairman

As a result, North America drove the growth in Q3 due to this issue, as well as the previously mentioned OEM wind-down is recognized in the international geographies. In terms of minimizing any impact from the logistics consolidation, we prioritized Infusion Systems products first, Infusion Consumables second, and Vital Care products third. So the business results I am going to describe momentarily reflect this hierarchy. In aggregate, there was no net impact to the revenue expectations for the company, but the overall mix was slightly impacted. Getting into our businesses more specifically, our Consumables business grew 5% in Q3 reported and was a record in absolute sales. We did have both good sequential growth and annual growth, as the step-up last year between Q2 and Q3 was substantial.

Vivek JainCEO and Chairman

Growth was driven more by the legacy ICU product lines of infusion therapy and oncology due to healthy census, share gains, and the hierarchy mentioned above. We continue to believe the business will deliver mid-single-digit growth for 2026 and likely follow the same trends as previous years. Our IV Systems business grew 11%, both reported and organic in Q3, and it was again a record quarter for the business. Dedicated sets generally followed the same trend as Consumables and capital sales were strong through the quarter, offset by declines in the OEM revenues. For Q4, we do feel some volume that we had scheduled for early 2027 is coming in earlier than planned, and as a result, we think this business will be at least high single digits for the full year 2026.

Vivek JainCEO and Chairman

Just wrapping up the businesses, in Q3, Vital Care decreased 10% on an organic basis and decreased 12% reported due largely to the logistics consolidation described above. We expect sequential improvements here, as we should have most of the challenges solved in Q4, but with the impact of the Q3 results, this business will have a larger year-over-year decrease than previously mentioned. There is nothing deeper here. We just have some cleanup of the integrations, which is happening as we speak, and it is basic blocking and tackling. With that, I will turn it over to Brian and then come back with some commentary to assess our financial performance. Financial performance and how it aligns with our strategic goals.

Brian BonnellCFO

Brian, over to you. Thanks, Vivek, and good afternoon, everyone.

Brian BonnellCFO

Since Vivek covered the Q3 revenue for each of the businesses, I will focus my remarks on recapping the Q3 performance for the remainder of the P&L, along with the Q3 balance sheet and cash flow, and then provide commentary on updates to our full-year guidance. As you can see from the GAAP to non-GAAP reconciliation in the press release, adjusted gross margin for the third quarter was 42%, which was in line with our expectations. The 42% gross margin rate represents a sequential improvement of approximately 1 percentage point relative to the second quarter gross margin of 41%, from a combination of integration synergies as well as favorable mix, with our higher-margin product lines of Consumables and Infusion Systems growing at a faster rate than certain lower-margin product lines within Vital Care.

Brian BonnellCFO

This quarter's gross margin improvement also demonstrates continued progress towards reaching our previously stated target of 43% by the time we exit 2027. It is worth noting that during the quarter, we recognized $8 million of tariff expense, which represents approximately 1.5% of adjusted revenue. We also received $11 million of IEEPA tariff refunds during the quarter. Consistent with the second quarter, we have excluded the full amount of the refunds from our non-GAAP income statement, and they therefore had no impact on the 42% adjusted gross margin rate. The refunds are, however, included in our free cash flow results for the quarter. To date, we have received tariff refunds totaling $31 million, which represent the vast majority of IEEPA tariffs previously paid. Hence, we do not expect significant additional refunds in future periods. Adjusted SG&A expense was $114 million in Q3, and adjusted R&D was $21 million.

Brian BonnellCFO

Total operating expenses were $135 million and represented 24.3% of revenue, which is a slight improvement relative to the Q2 rate of 24.5%, driven primarily by favorable expense leverage on a higher revenue base. There were not any unique or notable items in the Q3 operating expenses. Restructuring, integration, and strategic transaction expenses were $6 million in the third quarter, and related primarily to manufacturing and distribution network transfers and IT systems integration. The Q3 expense represents a significant step-down compared to historical levels of spend in this area, as we continue to close out several of the longer-term integration projects. Adjusted EBITDA for Q3 was $114 million, and EBITDA margin was 20.5%. EBITDA growth compared to last year was 8%, driven primarily by top-line growth of 4% for the quarter.

Brian BonnellCFO

The impact to Q3 adjusted EBITDA from our 40% equity investment in the joint venture was a loss of $1 million, which was consistent with our expectations as well as our commentary during the second quarter call, and was a similar level as Q3 of last year, reflecting typical seasonality for the business. Finally, adjusted diluted earnings per share for the quarter was $2.44 compared to $2.03 last year, an increase of 20%, driven by a combination of higher operating earnings, lower interest expense, and a lower tax rate. The current quarter results reflect net interest expense of $15 million as compared to $19 million last year, and an adjusted effective tax rate of 25% compared to 27% last year. Diluted shares outstanding for the quarter were 25.1 million. Now, moving on to cash flow and the balance sheet.

Brian BonnellCFO

For the quarter, free cash flow was very solid at $83 million, reflecting strong quality of earnings combined with $11 million from tariff refunds, lower restructuring and integration spending, and the benefit from CapEx timing. During the quarter, we invested $12 million of cash spend for quality system and product-related remediation activities, $6 million on restructuring and integration, and $16 million on CapEx for general maintenance and capacity expansion at our facilities, as well as placement of revenue-generating Infusion Systems with customers outside the U.S. Just to wrap up on the balance sheet, we finished the quarter with $1.16 billion of debt and $302 million of cash. The strong free cash flow allowed us to pay down $80 million of debt, bringing our net leverage ratio down to two times. Turning now to our 2026 guidance.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day